#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma byKathleen Lau May 19, 2022 0
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma byKathleen Lau December 18, 2021 0
#VisualAbstract Phase 3 trial shows adding clarithromycin to standard therapy does not improve progression-free survival in patients with multiple myeloma ineligible for autologous transplant byKathleen Lau May 28, 2021 0
#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma byKathleen Lau February 18, 2021 0
